Form 4: Nexien BioPharma CEO Acquires 1,000,000 Shares in Compensation Deal
SEC Form 4
Richard S. Greenberg, CEO of Nexien BioPharma, acquired 1,000,000 shares of common stock on May 23, 2024, as compensation for services.
Summary
- On May 23, 2024, Richard S. Greenberg, the CEO of Nexien BioPharma, acquired 1,000,000 shares of common stock.
- The acquisition was made as compensation for services rendered.
- Following the transaction, Greenberg directly owns 7,185,193 shares of Nexien BioPharma.
- Greenberg also holds various derivative securities, including warrants, convertible notes, and options to purchase common stock.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard filing showing compensation in the form of shares. The acquisition itself is neither overwhelmingly positive nor negative.
Positives
- The CEO's acquisition of shares, even as compensation, could be seen as a positive sign of confidence in the company's future.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- Shareholders may view the CEO's increased stake as a positive signal, aligning management's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 07/25/2018 | Date of options to purchase common stock (right to buy) at $0.54 |
| 10/26/2018 | Date of options to purchase common stock (right to buy) at $0.655 |
| 08/19/2020 | Date of options to purchase common stock (right to buy) at $0.08 |
| 11/24/2020 | Date of Class A, B, and C warrants |
| 05/23/2024 | Date of transaction where CEO acquired 1,000,000 shares |
| 06/30/2024 | Expiration date of convertible note |
| 07/25/2025 | Expiration date of options to purchase common stock (right to buy) at $0.54 |
| 10/26/2025 | Expiration date of options to purchase common stock (right to buy) at $0.655 |
| 11/24/2025 | Expiration date of Class A, B, and C warrants |
| 08/19/2027 | Expiration date of options to purchase common stock (right to buy) at $0.08 |
Keywords
NXEN, Nexien BioPharma, Richard S. Greenberg, Form 4, Beneficial Ownership, CEO, Shares, Warrants, Options, Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.